About amarantus bioscience holdings inc - AMBS
Amarantus BioScience Holdings, Inc. is a biopharmaceutical company, which engages in developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. It focuses on acquiring product and technology rights, raising capital, and performing research and development. The company was founded by Gerald E. Commissiong and John W. Commissiong on January 14, 2008 and is headquartered in New York, NY.
AMBS At a Glance
Amarantus Bioscience Holdings, Inc.
45 Wall Street
New York, New York 10005
| Phone | 1-650-862-5391 | Revenue | 95.33K | |
| Industry | Biotechnology | Net Income | -4,762,305.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2023 | |||
| View SEC Filings |
AMBS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 10.336 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -80.803 |
| Enterprise Value to Sales | 227.183 |
| Total Debt to Enterprise Value | 0.884 |
AMBS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.008 |
AMBS Liquidity
| Current Ratio | 0.001 |
| Quick Ratio | 0.001 |
| Cash Ratio | N/A |
AMBS Profitability
| Gross Margin | N/A |
| Operating Margin | -281.157 |
| Pretax Margin | -4,995.547 |
| Net Margin | -4,995.547 |
| Return on Assets | -38.229 |
| Return on Equity | N/A |
| Return on Total Capital | 86.181 |
| Return on Invested Capital | N/A |
AMBS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -346.353 |
| Total Debt to Total Assets | 187.502 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |